Abeona Therapeutics Inc. (ABEO)

8.25 +0.2 (+2.484%)

IEX Real-Time Price

November 16, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 8.05

Price Open 8

Volume: 436,459

Avg Volume: 710,778

Market Cap: 395.54M

P/E Ratio -8.59

52 Wk Range 6.94-22



ABEO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
45.92M
11.1M
15.82
24.17%

2018-09-28
45.92M
11.15M
19.70
24.29%

2018-09-14
45.92M
11.34M
25.04
24.70%

2018-08-31
45.92M
11.96M
26.98
26.04%




ABEO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-09
Q2 2018
N/A
-0.16 (5)
-0.25
-0.09

2018-05-21
Q1 2018
N/A
-0.19 (3)
0.00
0.00

2018-05-11
Q1 2018
N/A
-0.19 (3)
-0.18
0.01

2018-03-30
Q4 2017
N/A
-0.13 (3)
0.00
0.00

News

Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q3 2018 Results - Earnings Call Transcript (2018-11-12 14:17 SeekingAlpha)

Abeona Therapeutics Inc. (ABEO) Q3 2018 Results Earnings Conference Call November 12, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Analysts Liav Abraham - Citi Maury Raycroft - Jeffries Difeiā€¦

 


Statistics

Shares Outstanding: 47.94M

Top 15 Institution Percent: 71.80

Price To Sales: 72.26

Price To Book: 2.57

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -35.14

Return On Equity: -37.51

Profit Margin: N/A

Price History

Beta: 2.55

50-day Moving Avg: 10.84

200-day Moving Avg: 14.47

YTD Change: -52.03

5-day Change: 7.00

1-month Change: -21.05

3-month Change: -39.78

6-month Change: -60.71

1-year Change: -48.76

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Abeona Therapeutics Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.